Back to Browse Journals » Core Evidence » Volume 5

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer

Authors Rossana Berardi, Azzurra Onofri, Mirco Pistelli, et al

Published 24 September 2010 Volume 2010:5 Pages 61—76


Review by Single-blind

Peer reviewer comments 2

Rossana Berardi1, Azzurra Onofri2, Mirco Pistelli2, Elena Maccaroni2, Mario Scartozzi1, Chiara Pierantoni1, Stefano Cascinu1
1Clinica di Oncologia Medica, Università Politecnica delle Marche, Ospedali Riuniti Umberto I-GM Lancisi-G Salesi di Ancona, Italy; 2Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy

Abstract: Panitumumab is the first fully human monoclonal antibody to Epidermal Growth Factor Receptor (EGFR) to enter clinical trials for the treatment of solid tumors. The anti-tumor activity of panitumumab has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in numerous cancer models, particularly lung, kidney and colorectal (CRC). Preclinical and clinical studies have established a role for panitumumab in metastatic colorectal cancer (mCRC) refractory to multiple chemotherapeutic regimens. Based on these encouraging findings, panitumumab was approved by the US Food and Drug Administration for the treatment of patients with epidermal growth factor receptor-expressing mCRC refractory to fluoropyrimidine-, oxaliplatin-, and/or irinotecan-containing chemotherapeutic regimens. The improvement in progression free survival (PFS) and response rate (RR) produced by panitumumab monotherapy was significantly greater in patients with non mutated (wild-type) K-RAS than in those with mutant K-RAS. Therefore implementing routine K-RAS screening and limiting the use of EGFR inhibitors to patients with wild-type K-RAS appears the better strategy for select only the patients who could benefit from the therapy with panitumumab and also may have the potential for cost savings. The purpose of this review was to evaluate the patient-related, disease-related and economic-related evidence for the use of panitumumab in the treatment of metastatic colorectal cancer in clinical practice.

Keywords: colorectal cancer, EGFR; K-RAS, panitumumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer

Berardi R, Santoni M, Morgese F, Ballatore Z, Savini A, Onofri A, Mazzanti P, Pistelli M, Pierantoni C, De Lisa M, Caramanti M, Pagliaretta S, Pellei C, Cascinu S

OncoTargets and Therapy 2013, 6:563-576

Published Date: 21 May 2013

Readers of this article also read:

Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study

Montomoli J, Hamilton-Dutoit SJ, Frøslev T, Taylor A, Erichsen R

Clinical and Experimental Gastroenterology 2012, 5:167-171

Published Date: 18 September 2012

Filament formation associated with spirochetal infection: a comparative approach to Morgellons disease

Middelveen MJ, Stricker RB

Clinical, Cosmetic and Investigational Dermatology 2011, 4:167-177

Published Date: 14 November 2011

Translocation of PEGylated quantum dots across rat alveolar epithelial cell monolayers

Fazlollahi F, Sipos A, Kim YH, Hamm-Alvarez SF, Borok Z, Kim K-J, Crandall ED

International Journal of Nanomedicine 2011, 6:2849-2857

Published Date: 10 November 2011

Quantum dots affect expression of CD133 surface antigen in melanoma cells

Steponkiene S, Kavaliauskiene S, Purviniene R, Rotomskis R, Juzenas P

International Journal of Nanomedicine 2011, 6:2437-2444

Published Date: 20 October 2011

Synthesis and characterization of gold nanorods and their application for photothermal cell damage

Samim M, Prashant CK, Dinda AK, Maitra AN, Arora I

International Journal of Nanomedicine 2011, 6:1825-1831

Published Date: 31 August 2011

Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery

Wang YL, Li XM, Wang LY, Xu YL, Cheng XD, Wei P

International Journal of Nanomedicine 2011, 6:1497-1507

Published Date: 13 July 2011

Outer membrane protein secretin of type III secretion system of Vibrio vulnificus: structure prediction and orientation

Rama Adiga, Iddya Karunasagar, Indrani Karunasagar

Open Access Bioinformatics 2011, 3:61-66

Published Date: 14 February 2011

The potential carcinogenic risk of tanning beds: clinical guidelines and patient safety advice

Mette Mogensen, Gregor BE Jemec

Cancer Management and Research 2010, 2:277-282

Published Date: 28 October 2010

Frequency and clinical relevance of human bocavirus infection in acute exacerbations of chronic obstructive pulmonary disease

Felix C Ringshausen, Ai-Yui M Tan, Tobias Allander, Irmgard Borg, Umut Arinir, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:111-117

Published Date: 4 February 2009